(Q37483944)

20 August 2017

1 reference

title

Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors (English)

1 reference

20 August 2017

Kjell Oberg

1

1 reference

20 August 2017

1 May 2009

1 reference

Expert Review of Anticancer Therapy

20 August 2017

1 reference

20 August 2017

9

1 reference

20 August 2017

557-566

1 reference

20 August 2017

5

1 reference

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

20 August 2017

1 reference

The diagnosis and medical management of advanced neuroendocrine tumors.

21 January 2018

1 reference

Somatostatin receptor subtype expression in human tumors

21 January 2018

1 reference

Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands

21 January 2018

1 reference

Somatostatin and its receptor family

21 January 2018

1 reference

Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation

21 January 2018

1 reference

Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro

21 January 2018

1 reference

Opportunities in somatostatin research: biological, chemical and therapeutic aspects

21 January 2018

1 reference

Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities.

21 January 2018

1 reference

Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium

21 January 2018

1 reference

Growing vascular endothelial cells express somatostatin subtype 2 receptors

21 January 2018

1 reference

Somatostatin inhibits IGF-1 mediated induction of VEGF in human retinal pigment epithelial cells

21 January 2018

1 reference

Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients

21 January 2018

1 reference

Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells

21 January 2018

1 reference

The tyrosine phosphatase SHP-1 associates with the sst2 somatostatin receptor and is an essential component of sst2-mediated inhibitory growth signaling

21 January 2018

1 reference

Selective stimulation of somatostatin receptor subtypes: differential effects on Ras/MAP kinase pathway and cell proliferation in human neuroblastoma cells

21 January 2018

1 reference

Molecular signaling of somatostatin receptors.

21 January 2018

1 reference

Somatostatin receptor subtype-dependent regulation of nitric oxide release: involvement of different intracellular pathways.

21 January 2018

1 reference

Restoration of functional gap junctions through internal ribosome entry site-dependent synthesis of endogenous connexins in density-inhibited cancer cells

21 January 2018

1 reference

Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis

21 January 2018

1 reference

Activation of human somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53.

21 January 2018

1 reference

Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone

21 January 2018

1 reference

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action

21 January 2018

1 reference

Synthesis and biological activity of highly potent octapeptide analogs of somatostatin

21 January 2018

1 reference

Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

21 January 2018

1 reference

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

21 January 2018

1 reference

Neuroendocrine tumors. Peptide receptor radionuclide therapy

21 January 2018

1 reference

Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly

21 January 2018

1 reference

21 January 2018

1 reference

Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature.

21 January 2018

1 reference

Growth hormone secretion dynamics in a patient with ectopic growth hormone-releasing factor production.

21 January 2018

1 reference

Octreotide therapy for tumor-induced osteomalacia

21 January 2018

1 reference

Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review

21 January 2018

1 reference

Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors

21 January 2018

1 reference

High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours

21 January 2018

1 reference

Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report

21 January 2018

1 reference

Neuroendocrine tumors. Biotherapy

21 January 2018

1 reference

Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial

21 January 2018

1 reference

Effects of long term octreotide on gall stone formation and gall bladder function

21 January 2018

1 reference

Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors

21 January 2018

1 reference

Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly

21 January 2018

1 reference

Effect of the somatostatin analog octreotide on gastric mucosal function and histology during 3 months of preoperative treatment in patients with acromegaly.

21 January 2018

1 reference

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

21 January 2018

1 reference

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa

21 January 2018

1 reference

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

21 January 2018

1 reference

Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies

21 January 2018

1 reference

Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis

21 January 2018

1 reference

SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile

21 January 2018

1 reference

Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.09.26

1 reference

20 August 2017

1 reference

PubMed ID

19445573